Toggle menu

ATTEST2

Start date:
July 2017
End date:
January 2021
Co-ordinated by:
The Stroke Research Team
Main trial site:
NHS Greater Glasgow & Clyde

ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.

Trial Design
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III

Principal Investigator
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian

Local PI

Dr Matt Reed

Consultant and NRS Career Research Fellow in Emergency Medicine

Research Team

Rachel O'Brien

Lead Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA

Identification of Novel Psychoactive Substances (IONA)

This is a study looking at incidence and risk factors for poor ankle functional recovery, and the development and progression of post-traumatic ankle osteoarthritis after significant ankle ligament injury.

Read more

SALI Study

SALI study - Significant Ankle Ligament Injury

Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the Emergency Department

Read more

SNAP40

Evaluating the role of ambulatory, wireless vital sign monitoring in the detection of deterioration